Better Science, Better Health

“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.

“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.

“Better Science, Better Health” has three core areas of focus:

  • Harnessing real world evidence for better decision-making and create better patient outcomes
  • Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
  • Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines

Latest Events

Tomorrow’s Cures: Impacts of the International Pricing Index

Hosted by GIPC and Vital Transformation

Thursday, July 18, 2019 – 4:00 – 5:00 PM Capitol Hill Visitor’s Center (Room 209-08) First St. NE, Washington, DC 20515

We invite you to join us for a discussion on how the International Pricing Index (IPI) penalizes innovation by targeting companies with the most advanced, newest products. Join GIPC and Vital Transformation to discuss the impacts of IPI on patients, outcomes, and innovation.

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?

Wednesday, June 5, 2019
1:45 PM - 2:45 PM
BIO International Convention - Philadelphia, PA


Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.

Investing in EU Biotech IP – What Works?

4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET

In this webinar we:
• Highlight the results of the research
• Expand on the datapackage used
• Discuss the gap between EU and US IP productivity in healthcare
• Address the need for IP in the global biotech sector

VIEW ALL EVENTS

Latest News

Health care 2024: Privacy in the age of digital medicine


Duane Schulthess, managing Director of Vital Transformation, was invited as an expert by POLITICO to participate in “Health Care 2024,” a survey-driven series of online debates in which POLITICO will explore how the European Union can best tackle health policy.

In this installment of Health Care 2024 POLITICO asks: Can the EU gain benefits from sharing health data without weakening privacy — and if so, how?

Podcast Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation


Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics.

US Biotech Lobby Slams EU Reference Pricing

By CARMEN PAUN 4/9/19,
© POLITICO PRO Healthcare

U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.

VIEW ALL NEWS

Newsletter

Register now to receive all the latest news and events.

Latest Research

Our consultancy services

Videos

Visit our youtube channel to view all of our videos.

Webinar: RWE, CAR-T and Cancer – New Methods for Comparative Effectiveness

Webinar: "Investing in EU Biotech IP – What Works?" 4 Dec 2018